United Drugs Receives Buy Rating from N+1 Singer (UDG)
United Drugs (LON:UDG)‘s stock had its “buy” rating reiterated by N+1 Singer in a research note issued on Monday, AnalystRatings.NET reports. They currently have a GBX 350 ($5.74) price objective on the stock. N+1 Singer’s price objective would suggest a potential upside of 7.03% from the stock’s previous close.
A number of other firms have also recently commented on UDG. Analysts at Nplus1 Brewin upgraded shares of United Drugs to a “buy” rating in a research note to investors on Monday, December 2nd. They now have a GBX 350 ($5.74) price target on the stock, up previously from GBX 320 ($5.25). Separately, analysts at Investec cut their price target on shares of United Drugs from GBX 330 ($5.41) to GBX 305 ($5.00) in a research note to investors on Thursday, November 21st. They now have a “reduce” rating on the stock. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of GBX 336.25 ($5.52).
United Drugs (LON:UDG) traded up 2.29% during mid-day trading on Monday, hitting GBX 334.50. The stock had a trading volume of 59,087 shares. United Drugs has a 52-week low of GBX 255.00 and a 52-week high of GBX 361.80. The stock’s 50-day moving average is GBX 315. and its 200-day moving average is GBX 325.9. The company’s market cap is £805.6 million.
United Drug plc is a provider of services to healthcare manufacturers and pharmaceutical retailers, with operations in the United Kingdom, Ireland, the Netherlands, Belgium and the United States.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.